EMERGENT BIOSOLUTIONS INC. Finance Lease, Right-of-Use Asset, Amortization
EMERGENT BIOSOLUTIONS INC. (EBS) reported Finance Lease, Right-of-Use Asset, Amortization of $2.50 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-02-27
- EMERGENT BIOSOLUTIONS INC. finance lease, right-of-use asset, amortization for the quarter ending 2020-03-31 was $1.10M, a 83.33% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. finance lease, right-of-use asset, amortization for the quarter ending 2019-12-31 was $600.00K.
- EMERGENT BIOSOLUTIONS INC. finance lease, right-of-use asset, amortization for the quarter ending 2019-09-30 was $800.00K.
- EMERGENT BIOSOLUTIONS INC. finance lease, right-of-use asset, amortization for the quarter ending 2019-06-30 was $700.00K.
- EMERGENT BIOSOLUTIONS INC. finance lease, right-of-use asset, amortization for fiscal 2025 was $2.50M, a 21.88% decline from fiscal 2024.
- EMERGENT BIOSOLUTIONS INC. finance lease, right-of-use asset, amortization for fiscal 2024 was $3.20M, a 20.00% decline from fiscal 2023.
- EMERGENT BIOSOLUTIONS INC. finance lease, right-of-use asset, amortization for fiscal 2023 was $4.00M, a 28.57% decline from fiscal 2022.
- EMERGENT BIOSOLUTIONS INC. finance lease, right-of-use asset, amortization for fiscal 2022 was $5.60M, a 0.00% change from fiscal 2021.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|
| 2025-12-31 | $2.50M 10-K · filed 2026-02-27 | |||
| 2024-12-31 | $3.20M 10-K · filed 2026-02-27 | |||
| 2023-12-31 | $4.00M 10-K · filed 2026-02-27 | |||
| 2022-12-31 | $5.60M 10-K · filed 2025-03-04 | |||
| 2021-12-31 | $5.60M 10-K · filed 2024-03-08 | |||
| 2020-12-31 | $4.50M 10-K/A · filed 2023-12-11 | |||
| 2020-03-31 | $1.10M 10-Q · filed 2020-05-01 | $1.70M derived: sum of 2 quarters · filed 2022-02-25 | $2.50M derived: sum of 3 quarters · filed 2022-02-25 | $3.20M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $1.40M derived: sum of 2 quarters · filed 2022-02-25 | $2.10M derived: sum of 3 quarters · filed 2022-02-25 | $2.70M 10-K · filed 2022-02-25 |
| 2019-09-30 | $800.00K 10-Q · filed 2019-11-07 | $1.50M derived: sum of 2 quarters · filed 2019-11-07 | $2.10M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $700.00K 10-Q · filed 2019-08-02 | $1.30M 10-Q · filed 2019-08-02 | ||
| 2019-03-31 | $600.00K 10-Q · filed 2020-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |